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Objectives:  To study  the  role of  near-infrared  ﬂuorescence  imaging  in  the detection  and  resection  of
metastatic  cervical  lymph  nodes  in  head  and  neck  cancer.
Materials  and  methods:  CAL33  head  and neck  cancer  cells  of human  origin  were  implanted  in  the  oral
cavity  of nude  mice.  The  mice  were  followed  up after  tumor  resection  to detect  the development  of
lymph node  metastases.  A  speciﬁc  ﬂuorescent  tracer  for ˛vˇ3  integrin  expressed  by  CAL33  cells  was
injected  intravenously  in  the  surviving  mice  between  the second  and  the  fourth  month  following  tumor
resection.  A  near-infrared  ﬂuorescence-imaging  camera  was  used  to  detect  tracer  uptake  in metastatic
cervical  lymph  nodes,  to guide  of lymph-node  resection  for  histological  analysis.
Results: Lymph  node  metastases  were  observed  in  42.8%  of  surviving  mice  between  the  second  and
the  fourth  month  following  orthotopic  tumor  resection.  Near-infrared  ﬂuorescence  imaging  provided
real-time  intraoperative  detection  of clinical  and  subclinical  lymph  node  metastases.  These  results  were
conﬁrmed  histologically.
Conclusion: Near  infrared  ﬂuorescence  imaging  provides  real-time  contrast  between  normal  and  malig-
nant  tissue,  allowing  intraoperative  detection  of metastatic  lymph  nodes.  This  preclinical  stage  is essential
before testing  the technique  in humans.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
In head and neck squamous cell carcinoma (HNSCC), surgery
hould achieve complete resection with adequate safe margins. In
ddition to tumor resection, given the rate of lymph-node inva-
ion in HNSCC, which can be as high as 30% to 40% in patients
ithout any clinical adenopathy (cN0), neck dissection should in
rinciple be associated, for both diagnostic and therapeutic pur-
oses. It should be as complete as possible and should include all
he lymph-node areas in the lymphatic drainage territory of the
rimary tumor. In the literature there are few techniques allowing
eal-time intraoperative detection of metastatic lymph nodes. Such
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879-7296/© 2015 Elsevier Masson SAS. All rights reserved.techniques should optimize neck dissection by making it selective,
with only metastatic adenopathies being resected.
Near-infrared ﬂuorescence imaging for diagnosis, treatment and
follow-up of HNSCC is a fast developing ﬁeld. It provides real-time
information on the localization and extension of malignant tissue
through creation of a speciﬁc contrast between normal and cancer
tissue. It requires ﬂuorescent probes that speciﬁcally target cancer
cells. One of the most important targets is ˛vß3 integrin, which is
widely expressed on the surface of tumor-vessel endothelial cells
and by most tumor cells, including HNSCC, during migration or by
cells located on invasion frontlines [1–3]. Previous studies showed
that near-infrared ﬂuorescence imaging targeting vß3 integrin
provides beneﬁt in HNSCC surgery by improving resection quality
through the detection of tumor residue within the surgical bed that
would be invisible to the naked eye even under magnifying lenses,
so that the residue would be overlooked in purely macroscopically
guided resection. It was  further demonstrated that this detection of
cancer residues positively impacted recurrence-free survival in an
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rthotopic animal model of HNSCC, which was developed by our
eam [4,5].
The present study examined the role of near-infrared ﬂuo-
escence imaging in the detection and resection of metastatic
ervical adenopathies in our orthotopic animal model of HNSCC.
e injected a ﬂuorescent peptide speciﬁc for vß3 integrin in
rder to target cancer cells within adenopathies. This targeting was
isualized by a near-infrared ﬂuorescence-imaging device that was
reviously miniaturized and speciﬁcally adapted for future appli-
ations in HNSCC surgery.
. Material and methods
.1. Cell line
In our experiments, we used the CAL33 HNSCC cell line, supplied
ree of charge by the Antoine Lacassagne Cancer Center oncophar-
acology laboratory, Nice (France). It was established from a tissue
ample taken from a human oral cavity moderately differenti-
ted malpighian carcinoma [6], and showed stable expression of
uciferase gene by lentiviral transfection, allowing in vivo biolu-
inescence imaging to detect lymph-node metastases. Cells were
ept in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 10% fetal
alf serum in a humid incubator at 37 ◦C and an atmosphere con-
aining 5% CO2.
.2. Molecular targeting
AngioStampTM 800 (Fluoptics, Grenoble, France) is a peptide
oupled to a ﬂuorophore. It shows speciﬁc binding to ˛vˇ3 integrin.
t has a maximal absorbance at 781 nm and maximal emis-
ion at 794 nm.  It was injected intravenously into the mouse
ail under an inhaled general anesthesia, at 10 nmol per mouse
6–24 hours before ﬂuorescence acquisition. The in vivo ﬂuores-
ent signal was acquired by the near-infrared ﬂuorescence imaging
ystem described below.
.3. Near-infrared ﬂuorescence imaging system
FluoStickTM (Fluoptics, Grenoble, France) is a small-diameter
maging system, miniaturized and speciﬁcally adapted for future
pplications in HNSCC surgery [5]. It is intended for intraoperative
uorescence imaging using ﬂuorophores with maximal absorbance
round 770 nm and maximal emission around 820 nm.
.4. Orthotopic animal HNSCC model
The animals used in the study were female nude mice aged
–6 weeks, from Janvier Labs (Le Genest, Saint-Isle, France). The
xperimental protocol was approved by the French Education and
esearch Ministry (experimentation authorization no. 00392.02).
The orthotopic HNSCC model was previously described and
alidated [4,5]. Brieﬂy, a 0.5–1 mm tumor fragment from tumor
eveloping secondarily to subcutaneous CAL33 cell implantation
n adult mice was implanted in the inner aspect of the animal’s
heek (n = 14). Once developed, the tumor was completely resected
hrough an external incision of the cheek, under near-infrared ﬂo-
escence imaging after intravenous injection of AngioStampTM 800.
ice were followed up for 6 months post-explantation to detect
ate tumor recurrence and lymph-node metastasis through biolu-
inescence imaging which is described below, then sacriﬁced at
nd of follow-up or onset of tumor recurrence or clinical or subclini-
al lymph-node metastasis; weight-loss exceeding 15% and general
ealth deterioration also led to sacriﬁce.gy, Head and Neck diseases 132 (2015) 337–342
2.5. Bioluminescence imaging
In vivo bioluminescence imaging was used to track tumor
growth and detect recurrence and/or metastatic adenopathies.
Five minutes before acquisition, intraperitoneal luciferin injection
(150 mg/kg) was performed and then animals were kept under
general inhaled anesthesia (isoﬂurane 4% for induction and 1.5%
for maintenance) during bioluminescence acquisition on the IVIS
Kinetic system (Caliper Life Sciences).
2.6. Lymph-node surgery
When metastatic adenopathy was detected, AngioStampTM 800
was injected intravenously at 10 nmol per injection. Mice were
anesthetized with isoﬂurane 4% for induction and 1.5% for main-
tenance; 16–24 hours after injection, a ﬂuorescence acquisition
was taken before and after wide cervical incision exposing all the
anatomic structures of the neck. Mice were then sacriﬁced by cer-
vical dislocation. Suspect adenopathies and adenopathies showing
ﬂuorescent signal were resected and analyzed histologically. Con-
trol lymph nodes (unsuspicious, non-ﬂuorescent) were also excised
and analyzed.
2.7. Hematoxylin-eosin (H&E) staining
Lymph-node tumor cell detection was performed on histologic
slices with H&E staining. Samples were ﬁxed in 4% PFA, dehydrated
in successively increasing alcohol baths, then included in parafﬁn
and sliced by microtome with 7 m thickness. Slices were deparaf-
ﬁnized in xylene baths, rehydrated in successively decreasing
alcohol baths, then stained with hematoxylin for 4 minutes and
rinsed in ﬂowing water, stained with eosin for 2 minutes and rinsed
again in ﬂowing water. The stained slices were ﬁxed in 100% ethanol
then xylene, and slide mounted for histology under a BX41 Olympus
microscope.
3. Results
3.1. Development of an orthotopic model of lymph-node
metastasis in HNSCC
Fourteen mice with orthotopic HNSCC underwent complete
near-infrared ﬂuorescence-guided resection and were then fol-
lowed up for 6 months on bioluminescence imaging to detect
tumor recurrence or metastatic adenopathy. Four mice (28.5%) had
local recurrence during the ﬁrst 2 months. During the following
4 months, 3 mice showed signs of deteriorated general health
status with >15% weight loss, without recurrence or detectable
metastatic adenopathy, and were sacriﬁced. Bioluminescence
detected metastatic adenopathy (Fig. 1) in 3 of the 7 surviving
mice (42.8%) between the 3rd and 5th month post-implantation
(2nd to 4th month after orthotopic tumor explantation). When the
adenopathies were large, they were also detectable macroscopi-
cally and on palpation. Histologic analysis of resected suspicious
lymph nodes found metastasis of malpighian carcinoma (Fig. 2A).
3.2. Near-infrared ﬂuorescence imaging guided lymph-node
surgery in HNSCC
The detected metastatic adenopathies were sampled by near-
infrared ﬂuorescence-guided surgery after AngioStampTM 800
injection. In the absence of clinically detectable metastatic
adenopathy, preoperative bioluminescence imaging and pre- and
intra-operative ﬂuorescence imaging showed no cervical ﬂuores-
cent signal (Fig. 3A). Histologic analysis of a sampled control lymph
node found no abnormality (Fig. 3A, yellow arrow). Conversely,
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Fig. 1. Detection of metastatic adenopathies. Metastatic lymph nodes could be either detected on bioluminescence imaging or macroscopically (A). In some cases, metastatic
lymph nodes are only detected by bioluminescence imaging (B).
Fig. 2. Histologic (H&E) lymph-node analysis. A. In metastatic adenopathy, squamous cell carcinoma (dotted arrow) inﬁltrates almost the entire lymph node; note also the
interface (star) between residual lymphocyte population (arrow) and metastasis. B. Control lymph node, showing a structure free of any tumor invasion.
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Figure 3. Contribution of near-infrared ﬂuorescence imaging in HNSCC lymph-node surgery. Mouse A presents no detectable metastatic adenopathy on macroscopic exam-
ination,  bioluminescence imaging or ﬂuorescence imaging. Mouse B presents a metastatic adenopathy macroscopically detectable as well as on pre- and intra-operative
bioluminescence and ﬂuorescence imaging; pathologic analysis conﬁrmed the metastatic character of the adenopathy (red arrow). Mouse C presents a cervical bioluminescent
signal, but no adenopathy is detectable preoperatively. Intra-operatively, a hypertrophic adenopathy (blue arrow) shows no ﬂuorescent signal; in contrast, an unsuspicious
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tymph node does show a ﬂuorescent signal (green arrow). Both adenopathies were s
hy  showed metastasis of squamous cell carcinoma, while the macroscopically sus
istologic analysis.
n case of macroscopically detectable preoperative adenopathy
Fig. 3B, red arrow) associated with a bioluminescence signal, a
uorescent signal was also observed on pre- and intra-operative
uorescence imaging (Fig. 3B, red arrow). Histologic analysis of
he hypertrophied ﬂuorescent lymph node demonstrated metas-
asis (Fig. 3B, red arrow). Finally, in case of adenopathy withd for histology and compared with a control lymph node. The ﬂuorescent adenopa-
s non-ﬂuorescent adenopathy and control lymph node showed no abnormality on
preoperative bioluminescence signal but macroscopically unde-
tectable due to lack of morphological signs of malignancy (Fig. 3C),
a signal was observed only on intraoperative ﬂuorescence imaging
(Fig. 3C, green arrow). This lymph node did not seem suspicious on
intraoperative macroscopic examination, unlike another hypertro-
phied but non-ﬂuorescent node (Fig. 3C, blue arrow). Histologic
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nalysis showed the ﬂuorescent adenopathy to be metastatic
Fig. 3C, green arrow) and the hypertrophied non-ﬂuorescent node,
ike a control node, to be normal (Fig. 3C, blue and yellow arrows).
he results of near-infrared ﬂuorescence imaging-guided lymph-
ode surgery demonstrated that ﬂuorescence imaging effectively
uided intraoperative sampling of metastatic lymph nodes, even
hen clinically undetectable.
. Discussion
Development and assessment of new diagnostic and therapeu-
ic tools for HNSCC require prior testing in a suitable animal model,
hich needs to be reproducible and representative of HNSCC. In a
revious study, our team developed an orthotopic animal model of
NSCC, with 30 days’ survival with in situ tumor. We  opted for oral
avity implantation of tumor fragments rather than directly inject-
ng tumor cells [5]. In other orthotopic models described in the
iterature, cell injection may  induce dissemination of cancer cells by
he hydrostatic pressure from the syringe during injection, result-
ng in the rapid development of large tumors, requiring sacriﬁce
nd thus making it difﬁcult for lymph-node metastasis to develop
7–9]. In certain orthotopic animal HNSCC models using cell injec-
ion, the cervical lymph-node metastases that did develop may
ave been due to cell dissemination by hydrostatic pressure in the
ymph vessels during injection rather than to cell migration from
he primary site [9,10]. Such models thus fail to reproduce the real-
ty of the lymph-node metastasis process. The present orthotopic
nimal model of HNSCC allowed tumor resection without sacriﬁce,
nd thus long follow-up to detect tumor recurrence and the devel-
pment of metastatic adenopathy. The present study demonstrated
hat the model allowed metastatic adenopathy to develop in 42.8%
f mice between the 2nd and 4th month after tumor resection, a
ercentage approximating the 30–40% rate of lymph-node invasion
n human HNSCC. The model thus faithfully represents all charac-
eristics of HNSCC, enabling the impact of new surgical or medical
echniques on the primary site and on metastatic adenopathy to be
ssessed.
Several strategies have been suggested for ﬂuorescence
maging-guided HNSCC surgery. Clinical application requires phar-
acokinetic study of each new ﬂuorescent probe. Indocyanine
reen (ICG) was one of the ﬁrst ﬂuorophores tested in near-infrared
uorescence-guided HNSCC surgery and proved effective in detec-
ing sentinel nodes. It shows passive drainage by the lymphatic
ystem. Rather than speciﬁcally targeting cancer tissue, ICG is taken
p by the enhanced permeability and retention (EPR) effect [7],
n which the large diameter of endothelial fenestration, hemody-
amic changes within tumoral neovessels and the low level of
ymphatic drainage of tumors leads to an accumulation of parti-
les and small agents in the tumor tissue. ICG is thus not useful
or optimizing HNSCC resection margins or detecting lymph-node
etastasis [11–13]. Fluorescent probes speciﬁcally targeting recep-
ors expressed by HNSCC, in contrast, provide real-time distinction
etween cancerous and healthy tissue.
One of the most important targets of ﬂuorescent probes in oncol-
gy is avß3 integrin, which shows large expression in neovessels
nd certain tumors, including HNSCC [1–3]. It plays an impor-
ant role in angiogenesis, cell proliferation and migration and
etastasis. Among probes targeting avß3, the RAFT-c(-RGDfK-)4
regioselectively addressable functionalized template-arginine-
lycine-aspartic acid) peptide showed speciﬁcity in vitro and in vivo
nd has been coupled to many ﬂuorophores to create speciﬁc ﬂu-
rescent probes such as AngioStampTM 800, used in the present
tudy [14–16].
The present study conﬁrmed previous ﬁndings in the opti-
ization of tumor resection under near-infrared ﬂuorescence
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imaging. The local recurrence rate was 28.5% in the ﬁrst 2 months
after resection, in agreement with our previous rate of 25 ± 5%
[5]. AngioStampTM 800 was  also injected intravenously in sur-
viving mice between the 2nd and 4th month post-explantation.
Near-infrared ﬂuorescence imaging detected clinically observed
adenopathies but also those undetectable macroscopically pre-
or intra-operatively; their metastatic character was  conﬁrmed
by histology. In mice with cervical adenopathies on clinical
examination and/or with bioluminescent cervical signal, near-
infrared ﬂuorescence imaging was thus able to conﬁrm metastatic
status. Intra-operatively, it also helps the surgeon remove a
targeted metastatic adenopathy that is undetectable pre- or intra-
operatively. Real-time near-infrared ﬂuorescence imaging thus
provides real beneﬁt, speciﬁcally in HNSCC, guiding neck dissec-
tion so as exhaustively to resect metastatic cervical adenopathies
and optimize neck dissection.
5. Conclusion
Near-infrared ﬂuorescence imaging is a promising and precious
tool in HNSCC surgery. As well as improving tumor resection qual-
ity in the present orthotopic animal mode, it guided resection of
clinically unidentiﬁable metastatic adenopathies. The present pre-
clinical study is indispensable before human trials.
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